Brincidofovir (BCV)
Brincidofovir (BCV) is an oral antiviral designed to treat viral infections like smallpox by drug delivery to the intracellular site of viral replication. BCV penetrates cells via its lipid conjugate technology, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.
Availability: In Development
Manufacturer |
| Chimerix, Inc. |
Product Name |
| Brincidofovir (BCV) |
Detection Category |
| Biological |
Detection Method |
| PPE/Decon; |
Application |
| Personal Protective Equipment; |
Equipment Type |
| PPE |
Product Synopsis |
| Brincidofovir (BCV) is an oral antiviral designed to treat viral infections like smallpox by drug delivery to the intracellular site of viral replication. BCV penetrates cells via its lipid conjugate technology, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication. |
Availability |
| In Development |
Technology Readiness Level (TRL) |
| 6 |
User Feedback Sources |
| Indifferent/No user feedback |
Transportability |
| Pocket Size |
Live Agent Tested |
| Yes |
Operating Time |
| Immediate post-exposure use |
Training Required |
| <1 hour training |
Training Available |
| Yes |
Manuals Available |
| Yes |